STOCK TITAN
  1. Home
  2. News
  3. AXDX

Accelerate Diagnostics Inc - AXDX STOCK NEWS

Welcome to our dedicated news page for Accelerate Diagnostics (Ticker: AXDX), a resource for investors and traders seeking the latest updates and insights on Accelerate Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Accelerate Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Accelerate Diagnostics's position in the market.

News
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Accelerate Diagnostics, Inc. (AXDX) announced financial results for Q4 and full year 2023, highlighting progress in developing Accelerate Wave™. Despite a net loss of $13.0 million for Q4 and $61.6 million for the year, the company saw positive achievements in the Wave program and customer base expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.1%
Tags
earnings
-
News
Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
Rhea-AI Summary
Accelerate Diagnostics, Inc. (AXDX) will host a conference call to review 2023 fourth quarter and full year results on March 28, 2024, at 4:30 p.m. Eastern Time. The call can be accessed online or by phone with replay options available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
-
News
Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
Rhea-AI Summary
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced the pricing of an underwritten public offering of 6,860,659 units, consisting of common stock and warrants. The public offering price for each unit is $1.50, and for each pre-funded unit is $1.49. The company granted the underwriters a 30-day option to purchase additional shares and/or warrants. The gross proceeds from the offering, before deducting expenses, are expected to be $10.3 million. The offering is expected to close on or around January 24, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.6%
Tags
offering
News
Accelerate Diagnostics Announces Launch of Proposed Public Offering
Rhea-AI Summary
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock and/or additional warrants. William Blair & Company, L.L.C. is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.51%
Tags
offering
-
News
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
Rhea-AI Summary
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced preliminary, unaudited results for the quarter and year ended December 31, 2023. The company made significant progress in the development of their next-generation rapid Antimicrobial Susceptibility Testing system, Accelerate WaveTM, and expanded and secured their Pheno® customer base. Preliminary revenue for the year was approximately $12.1 million, reflecting a challenging capital sales environment. The company ended the year with approximately $13.4 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
earnings
-
News
Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
Rhea-AI Summary
Accelerate Diagnostics, Inc. (AXDX) collaborates with Bruker Corporation (BRKR) to bring rapid, automated microbial identification directly from positive blood culture samples. The agreement validates the use of Accelerate Diagnostics' Arc™ system with Bruker's MALDI Biotyper® sirius instruments and Sepsityper® software for registration in the US and EMEA markets. The Arc™ system enables on-demand processing of samples without the need for overnight culture incubation, reducing wait time for identification results. It competes with molecular positive blood culture identification solutions, offering potential cost savings and reduced likelihood of false positive results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
none
News
Accelerate Diagnostics Reports Third Quarter 2023 Results
Rhea-AI Summary
AXDX - Accelerate Diagnostics, Inc. Announces Q3 2023 Financial Results, Including 10% Increase in Net Sales and Wave Program Advances
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
earnings
-
News
Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.
Rhea-AI Summary
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) will host a conference call on November 9, 2023, at 4:30 p.m. ET to review 2023 Q3 results. The call can be accessed online at ir.axdx.com. A replay will be available for 30 days. Dial-in options are also provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
earnings
-
News
Accelerate Diagnostics Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
earnings
News
Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results
Rhea-AI Summary
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) will host a conference call on August 10, 2023, at 4:30 p.m. Eastern Time to review their second quarter results. The audio webcast can be accessed at ir.axdx.com. A replay of the call will be available for 30 days. Phone participants can dial +1.877.883.0383 (U.S.) or +1.412.902.6506 (International) with the Elite Entry Number: 4614555. The replay can be accessed by phone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) with the replay code 8685802 until August 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
earnings
Stock AXDX logo
Accelerate Diagnostics Inc

Nasdaq:AXDX

AXDX Rankings

#3231 Ranked by Market Cap
#4718 Ranked by Stock Gains
N/A Ranked by Dividends

AXDX Stock Data

19.24M
13.50M
36.8%
12.06%
1.35%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
US
Tucson

About AXDX

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.